Peer-Reviewed Publication
Altern Lab Anim2025;53(1):26-41.January 1, 2025Journal Article
The Use of MPS in Three Rs and Regulatory Applications: Perspectives From Developers on Stakeholder Responsibilities.
Megan R LaFollette1, Szczepan W Baran2, J Lowry Curley3, Anne M Dickinson4, Trivia Frazier5, Nina Hobi6, Ming-I Huang7, Victoria Hutter8, Benoît G C Maisonneuve9, Graham A Marsh10, Rhamiya Mahendran8, Iris Müller11, Xiaohua Qian12, Dharaminder Singh13, William R Thelin14, Jelena Vukasinovic15, Pelin L Candarlioglu16, Clive S Roper17
1The 3Rs Collaborative, Denver, CO, USA.
2VeriSim Life, Inc., San Francisco, CA, USA.
3AxoSim, Inc., New Orleans, LA, USA.
4Alcyomics Ltd, Newcastle upon Tyne, UK.
5Obatala Sciences, New Orleans, LA, USA.
6AlveoliX AG Swiss Organs-on-Chip Innovation, Bern, Switzerland.
7Aracari Biosciences, Inc., Irvine, CA, USA.
8ImmuONE, Stevenage, UK.
9NETRI, Lyon, France.
10Critical Path Institute, Tucson, AZ, USA.
11Unilever Safety and Environmental Assurance Centre, Sharnbrook, UK.
12Xellar Biosystems, Boston, MA, USA.
13CN Bio, Cambridge, UK.
14Altis Biosystems, Durham, NC, USA.
15Lena Biosciences, Atlanta, GA, USA.
16Complex In Vitro Models, GSK, Stevenage, UK.
17Roper Toxicology Consulting Limited, Edinburgh, UK.
Abstract
Increasing the use of microphysiological systems (MPS) in Three Rs and regulatory applications is a nuanced but important goal, which would also help increase their scientific impact. There are three distinct and important stakeholder groups that each play a unique role in expediting the use of MPS for regulatory purpose - namely, commercial MPS developers, end-users and regulators. Additionally,…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans